Challenges and limits of therapeutic de-escalation for papillomavirus-related oropharyngeal cancer
Copyright © 2022. Published by Elsevier Masson SAS..
The incidence of HPV-related oropharyngeal cancers has been increasing in Western countries for several decades. If they are individualized within the latest TNM classification, the current standards of management do not authorize the management of these patients to be singled out. However, their distinct oncogenesis and their excellent prognosis compared to other patients has allowed the development of several clinical trials based on the question of therapeutic de-escalation. This review of the literature aims to take stock of the elements provided by clinical research in recent years.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 26(2022), 6-7 vom: 24. Okt., Seite 921-924 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Enjeux et limites de la désescalade thérapeutique dans la prise en charge du cancer de l’oropharynx lié au papillomavirus |
|---|
| Beteiligte Personen: |
Modesto, A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 20.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2022.06.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345476344 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345476344 | ||
| 003 | DE-627 | ||
| 005 | 20231226025136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.canrad.2022.06.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1151.xml |
| 035 | |a (DE-627)NLM345476344 | ||
| 035 | |a (NLM)36030192 | ||
| 035 | |a (PII)S1278-3218(22)00120-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Modesto, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Challenges and limits of therapeutic de-escalation for papillomavirus-related oropharyngeal cancer |
| 246 | 3 | 3 | |a Enjeux et limites de la désescalade thérapeutique dans la prise en charge du cancer de l’oropharynx lié au papillomavirus |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 20.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Masson SAS. | ||
| 520 | |a The incidence of HPV-related oropharyngeal cancers has been increasing in Western countries for several decades. If they are individualized within the latest TNM classification, the current standards of management do not authorize the management of these patients to be singled out. However, their distinct oncogenesis and their excellent prognosis compared to other patients has allowed the development of several clinical trials based on the question of therapeutic de-escalation. This review of the literature aims to take stock of the elements provided by clinical research in recent years | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer de l’oropharynx | |
| 650 | 4 | |a Désescalade thérapeutique | |
| 650 | 4 | |a Human papillomavirus | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Immunothérapie | |
| 650 | 4 | |a Oropharyngeal cancer | |
| 650 | 4 | |a Papillomavirus humain | |
| 650 | 4 | |a Radiotherapy | |
| 650 | 4 | |a Radiothérapie | |
| 650 | 4 | |a Therapeutic de-escalation | |
| 700 | 1 | |a Graff Cailleaud, P |e verfasserin |4 aut | |
| 700 | 1 | |a Blanchard, P |e verfasserin |4 aut | |
| 700 | 1 | |a Boisselier, P |e verfasserin |4 aut | |
| 700 | 1 | |a Pointreau, Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 26(2022), 6-7 vom: 24. Okt., Seite 921-924 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:6-7 |g day:24 |g month:10 |g pages:921-924 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2022.06.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 6-7 |b 24 |c 10 |h 921-924 | ||